Page last updated: 2024-11-06

bometolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Bometolol is a beta blocker with a chemical structure similar to that of propranolol. It is a racemic mixture of two enantiomers, (S)-bometolol and (R)-bometolol. It is primarily used to treat hypertension. Its mechanism of action is believed to be due to its ability to block beta-adrenergic receptors in the heart and blood vessels, which leads to a decrease in heart rate and blood pressure. Bometolol is well-absorbed after oral administration and has a moderate duration of action. It is metabolized in the liver and excreted in the urine. Bometolol is generally well tolerated, but side effects such as fatigue, dizziness, and nausea may occur. It is contraindicated in patients with bradycardia, severe heart failure, and asthma. It is also important to note that bometolol can interact with other medications, so it is essential to consult with a healthcare professional before taking it. Bometolol has been studied for its potential to treat a variety of conditions, including glaucoma, migraine headaches, and anxiety disorders. However, more research is needed to determine its efficacy for these indications.'

bometolol: cardiospecific beta-adrenergic blocking drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68850
CHEMBL ID1742442
SCHEMBL ID1477805
MeSH IDM0077932

Synonyms (19)

Synonym
bometolol
opc-1427
5-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]-8-(2-oxopropoxy)-3,4-dihydro-1h-quinolin-2-one
SCHEMBL1477805
CHEMBL1742442
bometolol [inn]
bometololum [inn-latin]
unii-55qm6y09zy
55qm6y09zy ,
65008-93-7
2(1h)-quinolinone, 5-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-8-(2-oxopropoxy)-
(+-)-8-(acetonyloxy)-5-(3-((3,4-dimethoxyphenethyl)amino)-2-hydroxypropoxy)-3,4-dihydrocarbostyril
opc 1427
bometololum
(+/-)-8-(acetonyloxy)-5-(3-((3,4-dimethoxyphenethyl)amino)-2-hydroxypropoxy)-3,4-dihydrocarbostyril
bometolol [jan]
Q27261329
DTXSID30867108
5-(3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-hydroxypropoxy)-8-(2-oxopropoxy)-3,4-dihydroquinolin-2(1h)-one

Research Excerpts

Overview

Bometolol is a cardiospecific beta-adrenergic blocking drug.

ExcerptReferenceRelevance
"Bometolol is a cardiospecific beta-adrenergic blocking drug. "( Acute and subchronic effects of bometolol on blood pressure in hypertensive rats.
Hasegawa, Y; Kawashima, K; Kudo, Y; Sokabe, H; Watanabe, TX; Watanabe, Y, 1981
)
1.99

Treatment

ExcerptReferenceRelevance
"Bometolol treatment at the above doses decreased plasma renin activity, heart and kidney weights, and incidence of vascular lesion in either hypertensive rat."( Acute and subchronic effects of bometolol on blood pressure in hypertensive rats.
Hasegawa, Y; Kawashima, K; Kudo, Y; Sokabe, H; Watanabe, TX; Watanabe, Y, 1981
)
1.27

Dosage Studied

ExcerptRelevanceReference
" Thus shifts of the dose-response curves in BP and HR were observed."( A simple method to determine the ratio of cardiac to vascular beta-receptor blockade in the rat in vivo.
Kudo, Y; Sokabe, H; Zehr, JE, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]